Eric Ehrke‐Schulz
YOU?
Author Swipe
View article: Valosin containing protein (VCP/p97) expression in laryngeal squamous cell carcinoma: clinical evaluation and implications for targeted therapy
Valosin containing protein (VCP/p97) expression in laryngeal squamous cell carcinoma: clinical evaluation and implications for targeted therapy Open
Purpose Valosin-containing protein (VCP/p97) is a key regulator of proteostasis and cellular stress response and has been linked to tumor progression and poor prognosis in various malignant diseases. However, data on its role in laryngeal …
View article: Adeno-associated virus (AAV)-TBX18 does not generate biological pacemaker activity, unlike AAV-Hcn2
Adeno-associated virus (AAV)-TBX18 does not generate biological pacemaker activity, unlike AAV-Hcn2 Open
Gene therapy-based biological pacemakers have been proposed as an alternative to their hardware-based counterparts. In this context, short-term ectopic expression of the T-box transcription factor 18 (TBX18) in the ventricle reportedly gen…
View article: Expression and prognosis of DSG-2, CXADR, CD46 in head and neck squamous cell carcinoma
Expression and prognosis of DSG-2, CXADR, CD46 in head and neck squamous cell carcinoma Open
No prognostic significance of the expression of DSG-2, CXADR or CD46 in HNSCC was seen. DSG-2, CXADR and CD46 are expressed in HNSCC, so that optimization of oncotherapy with adenoviral vectors appears promising. Due to the significantly i…
View article: Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications
Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications Open
Adenoviruses (Ad) have the potential to induce severe infections in vulnerable patient groups. Therefore, understanding Ad biology and antiviral processes is important to comprehend the signaling cascades during an infection and to initiat…
View article: ADEVO: Proof-of-concept of Adenovirus Directed EVOlution by random peptide display on the fiber knob
ADEVO: Proof-of-concept of Adenovirus Directed EVOlution by random peptide display on the fiber knob Open
Directed evolution of viral vectors involves the generation of randomized libraries followed by artificial selection of improved variants. Directed evolution only yielded limited results in adenovirus vector (AdV) development until now, ma…
View article: Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5
Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5 Open
Background Adenoviral vectors are among the most frequently used vectors for gene therapy and cancer treatment. Most vectors are derived from human adenovirus (Ad) serotype 5 despite limited applicability caused by pre‐existing immunity an…
View article: Muscle Specific Promotors for Gene Therapy – A Comparative Study in Proliferating and Differentiated Cells
Muscle Specific Promotors for Gene Therapy – A Comparative Study in Proliferating and Differentiated Cells Open
Background: Depending on the therapy approach and disease background, the heterogeneity of muscular tissues complicates the development of targeted gene therapy, where either expression in all muscle types or restriction to only one muscle…
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Data from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Data from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Oncolytic adenoviruses (OAd) represent an attractive treatment option for cancer. Clinical efficacy of commonly utilized human adenovirus type 5 (Ad5)-based oncolytic viruses is limited by variable expression levels of the coxsackie- and a…
View article: Data from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Data from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Oncolytic adenoviruses (OAd) represent an attractive treatment option for cancer. Clinical efficacy of commonly utilized human adenovirus type 5 (Ad5)-based oncolytic viruses is limited by variable expression levels of the coxsackie- and a…
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Figure from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
View article: Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table from Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo